A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations

  • Si Yeon Song
  • , Su Jeong Ha
  • , Ji Hye Park
  • , So Jung Park
  • , Seong Hoon Shin
  • , Chulho Oak
  • , Jun Yong Choi
  • , Seong Woo Yoon
  • , Jung A. Kim
  • , Seong Hoon Yoon
  • , Ji Woong Son
  • , Seung Joon Kim
  • , Hwa Seung Yoo

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science